CASE CCC IN THE NEWS
Avon's Sunflower Mile Becomes Weapon Against a Rare Childhood Cancer
The Plain Dealer - September 6, 2014
The latest manifestation is a crowd-gathering mile of sunflowers along Interstate 90 in Avon. It commemorates 7-year-old Maria McNamara of Avon Lake and shines a light on the private nonprofit that bears her name: the Prayers from Maria Foundation...Megan McNamara, Maria's mother, said today that the foundation is announcing a $250,000 grant to underwrite research by Dr. James P. Basilion, associate professor of radiology and biomedical engineering and member of the Case Comprehensive Cancer Center at Case Western Reserve University...Since their daughter's death, the couple has raised funds through various campaigns that include marathons and wine festivals. In 2010, they gave Dr. Bingcheng Wang, a Case Western Reserve University researcher working at MetroHealth Medical Center and member of the Case Comprehensive Cancer Center, the first grant of $100,000.
Cutting-edge Cancer Treatment Uses Laser to Zap Brain Tumors
Fox News - September 4, 2014
Meghan Schultz was 25 weeks pregnant when she started having seizures in the kitchen as she was preparing dinner in 2011...Schultz knew she would need another surgery, so in the fall of 2013, she opted for a new kind of laser treatment called Neuroblate. "A laser which is a couple millimeters in size is directed into the tumor, and then the neurosurgeon controls the laser with a [magnetic resonance imaging] MRI," said Dr. Manmeet Ahluwalia, a medical oncologist and associate director of clinical trials operations at the Cleveland Clinic and Case Comprehensive Cancer Center member. "We heat the tumors to kill the tumor cells."
Discovery of a Single Genetic Mutation in Castration-Resistant Prostate Cancer Could Lead to New Biomarkers and Targeted Therapies
Department of Defense 2014 Prostate Cancer Highlights - September 2, 2014
The mechanisms that enhance DHT production from DHEA and promote abiraterone resistance in CRPC remain poorly understood. With this in mind and support from FY08 Physician Training Award, Case Comprehensive Cancer Center member Dr. Nima Sharifi and his multidisciplinary team of researchers at the University of Texas Southwestern Medical Center discovered a mutant version of the 3β hydroxysteroid dehydrogenase type 1 enzyme (3βHSD1), that was present in a subset of CRPCs. This mutation, N367T, prevents the enzyme from being ubiquitinated, a key part of the degradation process. By blocking ubiquitination, the 3βHSD1 is not degraded, and remains present in cancer cells much longer than the wild type version...Dr. Sharifi and his team, now located at the Cleveland Clinic Foundation, are working toward the identification of a small molecular inhibitor of this enzyme that may be used for prostate cancer therapy. The added potential for using the N367T mutation as a biomarker for CRPC further emphasizes the significance of this finding and its potential for impact in prostate cancer patients.
Genome Editing Edges to the Clinic
Genetic Engineering & Biotechnology News - September 1, 2014
Sigma has formed a partnership with Cleveland Clinic's Molecular Screening Core to develop a CRISPR [clustered regularly interspaced short palindromic repeats] core. This new core is part of the Case Comprehensive Cancer Center at Case Western Reserve University and is open for researchers at Cleveland Clinic and other biomedical research centers in the Cleveland area. One of core's first users, Paul Tesar, PhD, associate professor, department of genetics and genome sciences, Case Western Reserve University School of Medicine and Case Comprehensive Cancer Center member, uses gene-editing technology to study neurogenic and neurodevelopment disorders. Dr. Tesar's group focuses on areas of the brain that impact oligodendrocytes, which make myelin.
MARK YOUR CALENDARS
Fall 2014 Case CCC Clinical Research Retreat
The Case CCC will be holding a Clinical Research Retreat on October 7 in the Wolstein Research Building. A reception will be held from 5-5:30 pm, followed by presentations from 5:30-7 pm.
The agenda will focus on the theme of Immunotherapy:
James Finke, PhD: Strategies to Reduce Immune Suppression as a Means to Improve Immunotherapy: A laboratory perspective
Joseph Baar, MD: Recent Advances in the Immunotherapy of Cancer
Shaveta Vinayak, MD: Tumor Infiltrating Lymphocytes Predict for Response to Therapy in Triple-negative Breast Cancer
Mitchell Machtay, MD: National Clinical Trials Network/Cooperative Groups (NCTN) Update
2014 Adolescent and Young Adult Cancers Symposium
The 2014 Adolescent and Young Adult (AYA) Cancers Symposium will be held October 30-31, 2014 in the Wolstein Research Building. The focus of this two-day symposium will be on advancing AYA-related research, increasing federal funding, and exploration of scientific, clinical and psychological considerations in the AYA population.
Program highlights include a keynote address by Clifton Leaf, Deputy Managing Editor of Fortune Magazine and author of The Truth in Small Doses Why We're Losing the War on Cancer – And How to Win It.
Registration and program details soon to follow! For additional information or questions, please emailAYASYM2014@UHhospitals.org.
DoD Breast Cancer Research Program
Applications to the Fiscal Year 2014 (FY14) Breast Cancer Research Program (BCRP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program (DHP), by the U.S. Army Medical Research Acquisition Activity (USAMRAA). The intent of the Breakthrough Awards are to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:
Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required.
Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward clinical translation. Demonstration of efficacy in in vivo models, as applicable.
Pre-Application/LOI Deadline: December 3
Application Deadline: December 17
Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects.
Pre-Application (Preproposal) Deadline: October 22
Invited Application Deadline: January 29, 2015
Worldwide Cancer Research
Worldwide Cancer Research is accepting applications for research funding. The goal of the organization is to fund scientific research that may, in future, help reduce the incidence of cancer or improve cancer survival. The organization offers funding to support basic or translational research into the causes, mechanisms, diagnosis, treatment or prevention of cancer.
Deadline: October 31, 2014; April 24, 2015
Cancer Research Institute
The Cancer Research Institute (CRI) offers its Clinic and Laboratory Integration Program (CLIP) Grants to qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies. The program supports basic, pre-clinical, and translational research that can be directly applied to optimizing cancer immunotherapy in the clinic. Candidates for a CLIP Grant must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. CRI has no citizenship restrictions, and research supported by the award may be conducted at medical schools and research centers in the United States or abroad.
Deadline: November 1
Free to Breathe
Free to Breathe has a new funding opportunity solely focused on research to prevent or stop lung cancer metastasis. We seek to support high-impact and innovative lung cancer research within this area of emphasis that will result in clinical translation (e.g. clinical trial) by the end of the 3-year award period. Our ultimate goal is to fund research that will result in treatments for lung cancer patients and increase survival. At the time of application, the PIs must hold a doctoral degree (MD, PhD, DO, DrPH, or equivalent), and be independent investigators at or above the level of Assistant Professor (or equivalent).
Deadline: November 7
Melanoma Research Alliance
The Melanoma Research Alliance (MRA) announces its eighth annual Request for Proposals (RFP), soliciting translational research grant applications from scientists and clinicians around the world. The RFP calls for ideas that could lead to high impact near-term clinical application in melanoma detection, prevention, diagnosis, staging, or treatment. An investigator may serve as PI on only one proposal submitted to the MRA under any of the mechanisms in this cycle. This includes PIs on team science awards.
Full descriptions of each opportunity, including eligibility criteria and deadlines can be found here.
Deadlines for Young Investigator Award (including Dermatology Young Investigators), Established Investigator Award (including BMS-MRA Established Investigators), and Pilot Award (including SITC-MRA Pilot Award): November 11:
Deadlines for All Academic-Industry Partnership Award (for Established Investigators and Teams) and BMS-MRA Team Science Award: November 21